Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Operating Leases (2020 - 2025)

PROCEPT BioRobotics has reported Operating Leases over the past 6 years, most recently at $24.7 million for Q4 2025.

  • Quarterly results put Operating Leases at $24.7 million for Q4 2025, down 8.24% from a year ago — trailing twelve months through Dec 2025 was $24.7 million (down 8.24% YoY), and the annual figure for FY2025 was $24.7 million, down 8.24%.
  • Operating Leases for Q4 2025 was $24.7 million at PROCEPT BioRobotics, down from $27.4 million in the prior quarter.
  • Over the last five years, Operating Leases for PRCT hit a ceiling of $49.2 million in Q4 2021 and a floor of $1.4 million in Q1 2022.
  • Median Operating Leases over the past 5 years was $27.2 million (2023), compared with a mean of $25.4 million.
  • Biggest five-year swings in Operating Leases: tumbled 53.86% in 2022 and later skyrocketed 1929.62% in 2023.
  • PROCEPT BioRobotics' Operating Leases stood at $49.2 million in 2021, then tumbled by 53.86% to $22.7 million in 2022, then increased by 15.34% to $26.2 million in 2023, then rose by 2.62% to $26.9 million in 2024, then decreased by 8.24% to $24.7 million in 2025.
  • The last three reported values for Operating Leases were $24.7 million (Q4 2025), $27.4 million (Q3 2025), and $27.8 million (Q2 2025) per Business Quant data.